Fengmin Zhao

Also affiliated with Shanghai Medical Information Center, ECOG-ACRIN Cancer Research Group, People's Hospital of Cangzhou, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial”.

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial

Journal of Clinical Oncology(2023)10.1200/jco.23.00377

N/A

2.3DataRank · unranked

46 citations

Fengmin Zhao, Ju‐Whei Lee, Edward H. Ip, John Devin Peipert, Noah Graham +11 more

Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.3854

N/A

0.864DataRank · unranked

21 citations

Fengmin Zhao, Ju‐Whei Lee, Shu-en Shen, Edward H. Ip, Nathaniel S. O’Connell +12 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0.678DataRank · unranked

91 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

Cancer Medicine(2020)10.1002/cam4.3416

N/A

0.523DataRank · unranked

9 citations

Fengmin Zhao, Taofeek K. Owonikoko, Josephine Feliciano, Nisha Mohindra, Suzanne E. Dahlberg +10 more

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.24.00526

N/A

0.442DataRank · unranked

11 citations

Fengmin Zhao, Tarah J. Ballinger, Sofia F. Garcia, Fei Shen, Shamsuddin Virani +19 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19136

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +9 more

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

Cancer(2021)10.1002/cncr.33992

N/A

0.266DataRank · unranked

4 citations

Santiago Saldana, Kathy D. Miller, Ruth C. Carlos, Ilana F. Gareen, Joseph A. Sparano +9 more

Reply to T. Shimoi et al and Y. Shimanuki et al

Journal of Clinical Oncology(2021)10.1200/jco.21.01905

N/A

0.209DataRank · unranked

2 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +20 more

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Cancer(2024)10.1002/cncr.35187

N/A

0.208DataRank · unranked

3 citations

Fengmin Zhao, Ingrid A. Mayer, Amyé Tevaarwerk, Sofia F. Garcia, Carlos L. Arteaga +20 more

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19132

N/A

0.208DataRank · unranked

3 citations

John Devin Peipert, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +15 more

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201

The Oncologist(2025)10.1093/oncolo/oyaf416

N/A

0DataRank · unranked

0 citations

Fengmin Zhao, Neal J. Meropol, Bruce J. Giantonio, Robert B. Diasio, Patrick J. Flynn +14 more

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.605

N/A

0DataRank · unranked

7 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +12 more

Association between allostatic load, symptom burden and mortality in E1A11 trial for myeloma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12102

N/A

0DataRank · unranked

0 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, David Cella, Fengmin Zhao +9 more

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

Blood Cancer Journal(2022)10.1038/s41408-022-00648-y

N/A

0DataRank · unranked

25 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, Susanna Jacobus, Matthias Weiss +12 more

Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12094

N/A

0DataRank · unranked

0 citations

John Devin Peipert, Vered Stearns, Victor T. Chang, Opeyemi A. Jegede, Edward H. Ip +15 more

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7045

N/A

0DataRank · unranked

10 citations

Helga S. Marques, Gloria Xue, Richard L. Hoffman, Constantine Gatsonis, Fengmin Zhao +4 more

Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments

Cancer(2025)10.1002/cncr.70084

N/A

0DataRank · unranked

2 citations

Shaili Ganatra, Fengmin Zhao, Ju‐Whei Lee, Jessica Roydhouse, Edward H. Ip +13 more